Medtronic announced the results of an analysis on the impact of stroke severity in patients receiving its HeartWare HVAD System as destination therapy, showing that targeted blood pressure management helped reduce serious strokes. The HVAD System is a left ventricular assist device that helps increase the amount of blood that circulates through the body in patients with advanced heart failure; the destination therapy indication refers to patients who are not candidates for heart transplants. The retrospective analysis, presented at the 2019 International Society for Heart and Lung Transplantation Scientific Sessions, used data from both the ENDURANCE and ENDURANCE Supplemental randomized trials, the company said.
https://thefly.com/landingPageNews.php?id=2889211
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.